Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer.
Perrone G, Ruffini PA, Catalano V, Spino C, Santini D, Muretto P, Spoto C, Zingaretti C, Sisti V, Alessandroni P, Giordani P, Cicetti A, D'Emidio S, Morini S, Ruzzo A, Magnani M, Tonini G, Rabitti C, Graziano F. Perrone G, et al. Among authors: giordani p. Eur J Cancer. 2008 Sep;44(13):1875-82. doi: 10.1016/j.ejca.2008.05.017. Epub 2008 Jul 9. Eur J Cancer. 2008. PMID: 18617393
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer.
Catalano V, Loupakis F, Graziano F, Bisonni R, Torresi U, Vincenzi B, Mari D, Giordani P, Alessandroni P, Salvatore L, Fornaro L, Santini D, Baldelli AM, Rossi D, Giustini L, Silva RR, Falcone A, D'Emidio S, Rocchi M, Luzi Fedeli S. Catalano V, et al. Among authors: giordani p. Ann Oncol. 2012 Jan;23(1):135-141. doi: 10.1093/annonc/mdr062. Epub 2011 Apr 29. Ann Oncol. 2012. PMID: 21531784 Free article.
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.
Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, Bisonni R, Canestrari E, Ficarelli R, Menichetti ET, Mari D, Testa E, Silva R, Vincenzi B, Giordani P, Cascinu S, Giustini L, Tonini G, Magnani M. Ruzzo A, et al. Among authors: giordani p. J Clin Oncol. 2006 Apr 20;24(12):1883-91. doi: 10.1200/JCO.2005.04.8322. J Clin Oncol. 2006. PMID: 16622263
HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer.
Catalano V, Mellone P, d'Avino A, Shridhar V, Staccioli MP, Graziano F, Giordani P, Rossi D, Baldelli AM, Alessandroni P, Santini D, Lorenzon L, Testa E, D'Emidio S, De Nictolis M, Muretto P, Fedeli SL, Baldi A. Catalano V, et al. Among authors: giordani p. Histopathology. 2011 Apr;58(5):669-78. doi: 10.1111/j.1365-2559.2011.03818.x. Epub 2011 Mar 30. Histopathology. 2011. PMID: 21447133 Clinical Trial.
A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases.
Catalano V, Bisonni R, Graziano F, Giordani P, Alessandroni P, Baldelli AM, Casadei V, Rossi D, Fedeli SL, D'Emidio S, Giustini L, Fiorentini G. Catalano V, et al. Among authors: giordani p. Gastric Cancer. 2013 Jul;16(3):411-9. doi: 10.1007/s10120-012-0204-z. Epub 2012 Oct 11. Gastric Cancer. 2013. PMID: 23065042 Clinical Trial.
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial.
Santini D, Graziano F, Catalano V, Di Seri M, Testa E, Baldelli AM, Giordani P, La Cesa A, Spalletta B, Vincenzi B, Russo A, Caraglia M, Virzi V, Cascinu S, Tonini G. Santini D, et al. Among authors: giordani p. BMC Cancer. 2006 May 10;6:125. doi: 10.1186/1471-2407-6-125. BMC Cancer. 2006. PMID: 16686939 Free PMC article. Clinical Trial.
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, Vincenzi B, Giordani P, Alessandroni P, Testa E, Tonini G, Catalano G. Catalano V, et al. Among authors: giordani p. Br J Cancer. 2008 Nov 4;99(9):1402-7. doi: 10.1038/sj.bjc.6604732. Br J Cancer. 2008. PMID: 18971936 Free PMC article.
Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari D, Fornaro L, Baldelli AM, Giordani P, Rossi D, Alessandroni P, Giustini L, Silva RR, Falcone A, D'Emidio S, Fedeli SL. Catalano V, et al. Among authors: giordani p. Br J Cancer. 2009 Mar 24;100(6):881-7. doi: 10.1038/sj.bjc.6604955. Epub 2009 Mar 3. Br J Cancer. 2009. PMID: 19259089 Free PMC article.
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M. Ruzzo A, et al. Among authors: giordani p. J Clin Oncol. 2007 Apr 1;25(10):1247-54. doi: 10.1200/JCO.2006.08.1844. J Clin Oncol. 2007. PMID: 17401013
121 results